192 related articles for article (PubMed ID: 24481636)
1. [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Schnell O
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S70-4. PubMed ID: 24481636
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
3. [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
Seufert J
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S65-9. PubMed ID: 24481635
[No Abstract] [Full Text] [Related]
4. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Bailey RA; Damaraju CV; Martin SC; Meininger GE; Rupnow MF; Blonde L
Am J Manag Care; 2014 Jan; 20(1 Suppl):s16-24. PubMed ID: 24512193
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Jabbour SA; Hardy E; Sugg J; Parikh S;
Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
[TBL] [Abstract][Full Text] [Related]
7. [New class of oral antidiabetic drugs. Effective in combination with metformin].
MMW Fortschr Med; 2007 Jan; 149(1-2):17. PubMed ID: 17619359
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Ferrannini E; Berk A; Hantel S; Pinnetti S; Hach T; Woerle HJ; Broedl UC
Diabetes Care; 2013 Dec; 36(12):4015-21. PubMed ID: 24186878
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
11. [GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].
Menge BA; Meier JJ; Schmidt WE
Med Klin (Munich); 2010 Mar; 105(3):163-75. PubMed ID: 20349294
[No Abstract] [Full Text] [Related]
12. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Matthaei S
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Han KA; Chon S; Chung CH; Lim S; Lee KW; Baik S; Jung CH; Kim DS; Park KS; Yoon KH; Lee IK; Cha BS; Sakatani T; Park S; Lee MK
Diabetes Obes Metab; 2018 Oct; 20(10):2408-2415. PubMed ID: 29862619
[TBL] [Abstract][Full Text] [Related]
14. Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Bailey RA; Vijapurkar U; Meininger G; Rupnow MF; Blonde L
Clin Ther; 2015 May; 37(5):1045-54. PubMed ID: 25795432
[TBL] [Abstract][Full Text] [Related]
15. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Rosenstock J; Aggarwal N; Polidori D; Zhao Y; Arbit D; Usiskin K; Capuano G; Canovatchel W;
Diabetes Care; 2012 Jun; 35(6):1232-8. PubMed ID: 22492586
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Leiter LA; Yoon KH; Arias P; Langslet G; Xie J; Balis DA; Millington D; Vercruysse F; Canovatchel W; Meininger G
Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
[TBL] [Abstract][Full Text] [Related]
17. [SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Seufert J
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S52-8. PubMed ID: 24481633
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
Aschner P; Katzeff HL; Guo H; Sunga S; Williams-Herman D; Kaufman KD; Goldstein BJ;
Diabetes Obes Metab; 2010 Mar; 12(3):252-61. PubMed ID: 20070351
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
[TBL] [Abstract][Full Text] [Related]
20. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
Violante R; Oliveira JH; Yoon KH; Reed VA; Yu MB; Bachmann OP; Lüdemann J; Chan JY
Diabet Med; 2012 Nov; 29(11):e417-24. PubMed ID: 22375612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
